Approximately 15–25% of breast cancers are classified as HER2+, a sub-group of tumours with a more aggressive clinical phenotype and worse prognosis due to unregulated cell growth mediated by overexpression of the HER2 protein [18]. This evidence concerns the gene ERBB2 and neoplasm.